Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Mt. Sinai researchers report that aspirin reduces risk of first heart attack by one-third

23.09.2003


Aspirin reduces the risk of a first heart attack by 32 percent, according to a report by researchers at Mount Sinai Medical Center & Miami Heart Institute (MSMC-MHI) published in the current issue of Archives of Internal Medicine. The paper, which is based on a meta-analysis of five major randomized clinical trials (55,580 participants, 11,466 women) in primary prevention, also found that aspirin reduces the combined risk of heart attack, stroke and vascular death by 15 percent.



Charles H. Hennekens, M.D., Co-Director of Cardiovascular Research at MSMC-MHI, and Professor of Medicine & Epidemiology and Public Health at the University of Miami School of Medicine was the first to demonstrate the benefit of aspirin in reducing the risk of a first heart attack in a landmark Physicians’ Health Study (PHS), which was published in 1988 in the New England Journal of Medicine. Under his direction, Rachel S. Eidelman, M.D., a cardiology fellow at MSMC-MHI, performed the latest meta-analysis.

The findings strongly support the treatment guidelines issued by the American Heart Association (AHA), which recommends the use of aspirin for all men and women whose 10-year risks of a first coronary event are 10 percent or greater. The U.S. Preventive Services Task Force (USPSTF) released similar guidelines earlier in 2002, urging all healthcare providers to consider the use of aspirin in all apparently healthy men and women with a 6 percent or greater 10-year risk of a coronary event.


"The individual trials and their meta-analysis support the AHA and USPSTF guidelines, which note that the benefits of long-term aspirin use are likely to outweigh any risks for these individuals," Hennekens said. "The more widespread and appropriate use of aspirin in primary prevention could avoid hundreds of thousands of first heart attacks and important vascular events each year in the U.S."

The aspirin component of Dr. Hennekens trial, the PHS, was terminated early on January 25, 1988 based on the unanimous recommendations of the Data and Safety Monitoring Board, due primarily to a statistically extreme 44 percent reduction in risk of a first heart attack among those assigned at random to aspirin. There have been four primary prevention trials published since then, three of which showed similar positive findings for aspirin.

"We found that the current totality of evidence strongly supports our initial findings from the Physicians’ Health Study that aspirin significantly reduces the risk of a first heart attack in apparently healthy individuals," Hennekens added. "This data, along with the findings that aspirin reduces the risk of death by 23 percent if given during a heart attack and by 15 percent in a wide range of people who have survived prior cardiovascular events, demonstrate the need for wider utilization of aspirin."

"Yet despite the clearly demonstrated cardio-protective benefits of aspirin, this medication remains alarmingly underutilized among survivors of prior events, those having a heart attack and apparently healthy men and women, whose 10-year risk is 10 percent or more," Hennekens continued. "We hope the latest findings result in greater awareness on the part of healthcare providers and the general public and motivate increased aspirin utilization, which could result in significant reductions of premature cardiovascular deaths and first heart attacks."

Coronary heart disease is the single leading cause of death in the United States, accounting for more than 500,000 deaths annually. Approximately 80 percent of deaths from coronary heart disease in people under age 65 occur during the first heart attack.



Mount Sinai & Miami Heart’s Cardiovascular Center of Excellence is committed to being a leader in the prevention, diagnosis and treatment of heart disease. The medical center is the largest cardiac services provider in South Florida, conducting approximately 1,300 open heart procedures and approximately 7,400 diagnostic and therapeutic cardiac catheterizations annually.

For a physician referral, please call (305) 674-2273

Katie Cline | EurekAlert!

More articles from Health and Medicine:

nachricht Researchers release the brakes on the immune system
18.10.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht Norovirus evades immune system by hiding out in rare gut cells
12.10.2017 | University of Pennsylvania School of Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Neutron star merger directly observed for the first time

University of Maryland researchers contribute to historic detection of gravitational waves and light created by event

On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...

Im Focus: Breaking: the first light from two neutron stars merging

Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.

Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

Im Focus: Shrinking the proton again!

Scientists from the Max Planck Institute of Quantum Optics, using high precision laser spectroscopy of atomic hydrogen, confirm the surprisingly small value of the proton radius determined from muonic hydrogen.

It was one of the breakthroughs of the year 2010: Laser spectroscopy of muonic hydrogen resulted in a value for the proton charge radius that was significantly...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ASEAN Member States discuss the future role of renewable energy

17.10.2017 | Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

Climate Engineering Conference 2017 Opens in Berlin

10.10.2017 | Event News

 
Latest News

Researchers release the brakes on the immune system

18.10.2017 | Health and Medicine

Separating methane and CO2 will become more efficient

18.10.2017 | Life Sciences

Ocean atmosphere rife with microbes

17.10.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>